NCT02100475 - A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

insulin degludec/liraglutide

"Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin.~Dose individually adjusted."

DRUG

insulin aspart

Dose titration of insulin aspart will be based on the respective pre-meal(s) and bedtime SMPG measured daily.

Trial Locations (60)

1449

Novo Nordisk Investigational Site, Alberton

1685

Novo Nordisk Investigational Site, Midrand

2500

Novo Nordisk Investigational Site, Wollongong

3135

Novo Nordisk Investigational Site, East Ringwood

3300

Novo Nordisk Investigational Site, Eger

3400

Novo Nordisk Investigational Site, Corrientes

3526

Novo Nordisk Investigational Site, Miskolc

4029

Novo Nordisk Investigational Site, Herston

4226

Novo Nordisk Investigational Site, Robina

4305

Novo Nordisk Investigational Site, Ipswich

4400

Novo Nordisk Investigational Site, Salta

4450

Novo Nordisk Investigational Site, Durban

5700

Novo Nordisk Investigational Site, Gyula

9024

Novo Nordisk Investigational Site, Győr

16602

Novo Nordisk Investigational Site, Altoona

18012

Novo Nordisk Investigational Site, Granada

40503

Novo Nordisk Investigational Site, Lexington

41003

Novo Nordisk Investigational Site, Seville

41010

Novo Nordisk Investigational Site, Seville

42084

Novo Nordisk Investigational Site, Pachuca

45500

Novo Nordisk Investigational Site, Ioannina

46026

Novo Nordisk Investigational Site, Valencia

60031

Novo Nordisk Investigational Site, Gurnee

62250

Novo Nordisk Investigational Site, Cuernavaca

64460

Novo Nordisk Investigational Site, Monterrey

91701

Novo Nordisk Investigational Site, Trnava

93201

Novo Nordisk Investigational Site, Veľký Meder

93401

Novo Nordisk Investigational Site, Levice

93720

Novo Nordisk Investigational Site, Fresno

97101

Novo Nordisk Investigational Site, Prievidza

98057

Novo Nordisk Investigational Site, Renton

117036

Novo Nordisk Investigational Site, Moscow

123448

Novo Nordisk Investigational Site, Moscow

194354

Novo Nordisk Investigational Site, Saint Petersburg

194358

Novo Nordisk Investigational Site, Saint Petersburg

199034

Novo Nordisk Investigational Site, Saint Petersburg

400131

Novo Nordisk Investigational Site, Volgograd

420073

Novo Nordisk Investigational Site, Kazan'

610014

Novo Nordisk Investigational Site, Kirov

630117

Novo Nordisk Investigational Site, Novosibirsk

634034

Novo Nordisk Investigational Site, Tomsk

634041

Novo Nordisk Investigational Site, Tomsk

33316-2521

Novo Nordisk Investigational Site, Fort Lauderdale

70461-4231

Novo Nordisk Investigational Site, Slidell

B1704ETD

Novo Nordisk Investigational Site, Buenos Aires

C1056ABJ

Novo Nordisk Investigational Site, Capital Federal

B2800DGH

Novo Nordisk Investigational Site, Zárate

GR-11527

Novo Nordisk Investigational Site, Athens

GR-41110

Novo Nordisk Investigational Site, Larissa

GR-54642

Novo Nordisk Investigational Site, Thessaloniki

GR-57001

Novo Nordisk Investigational Site, Thessaloniki

03300

Novo Nordisk Investigational Site, Mexico City

08501

Novo Nordisk Investigational Site, Bardejov

02601

Novo Nordisk Investigational Site, Dolný Kubín

040 11

Novo Nordisk Investigational Site, Košice

05801

Novo Nordisk Investigational Site, Poprad

01701

Novo Nordisk Investigational Site, Považská Bystrica

0250

Novo Nordisk Investigational Site, Brits

04001

Novo Nordisk Investigational Site, Almería

07014

Novo Nordisk Investigational Site, Palma de Mallorca